Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells
Open Access
- 1 January 2008
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 111 (1), 453-462
- https://doi.org/10.1182/blood-2007-06-094482
Abstract
Based on their ability to control T-cell homeostasis, Foxp3+CD4+CD25+ regulatory T cells (Tregs) are being considered for treatment of autoimmune disorders andThis publication has 51 references indexed in Scilit:
- Endothelial Akt Signaling Is Rate-Limiting for Rapamycin Inhibition of Mouse Mammary Tumor ProgressionCancer Research, 2007
- Nonredundant roles for Stat5a/b in directly regulating Foxp3Blood, 2007
- Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T cells in prevention of acute graft-versus-host diseaseBlood, 2006
- Altered activation of AKT is required for the suppressive function of human CD4+CD25+ T regulatory cellsBlood, 2006
- A Foxy tango with NFATNature Immunology, 2006
- PTEN inhibits IL-2 receptor-mediated expansion of CD4+CD25+ TregsJCI Insight, 2006
- In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsetsBlood, 2005
- Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cellsBlood, 2005
- Prevention of lethal acute GVHD with an agonistic CD28 antibody and rapamycinBlood, 2005
- The influence of immunosuppressive drugs on tolerance induction through bone marrow transplantation with costimulation blockadeBlood, 2003